Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744209 | 1.00 | ALOX15 (0.51) | ALOX15KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL6872391 | 1.00 | ALOX15 (0.51) | ALOX15KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL8776709 | 0.87 | ALOX15 (0.49) | ALOX15KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL8776680 | 0.87 | ALOX15 (0.49) | ALOX15KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL11764494 | 0.87 | ALOX15 (0.51) | ALOX15KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL27620766 | 0.84 | MEN1 (0.45) | KMT2AALDH1A1GAALMNAMEN1 | |
| SCHEMBL10480695 | 0.84 | RAB9A (0.47) | KMT2AAOC3MEN1NPC1RAB9A | |
| SCHEMBL7082815 | 0.84 | RAB9A (0.47) | KMT2AAOC3MEN1NPC1RAB9A | |
| SCHEMBL9393808 | 0.84 | ALOX15 (0.49) | ALOX15KMT2AHDAC3HDAC4HDAC1 | |
| SCHEMBL25924790 | 0.84 | ALOX15 (0.49) | ALOX15KMT2AHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881839-B2 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-04-19 | — | — | US | claimed |
| US-20040127704-A1 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-07-01 | — | — | US | claimed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4615823-A2 | COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USE | Revolution Medicines, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250269037-A1 | COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USE | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-08-28 | — | — | US | disclosed |
| US-20250051306-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| US-20240262847-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-08 | — | — | US | disclosed |
| WO-2024102421-A2 | COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USE | Revolution Medicines, Inc. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4334324-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022235866-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4054720-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-6881839-B2 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-04-19 | — | — | US | disclosed |
| WO-2004058734-A1 | PROCESS FOR PREPARING DILTIAZEM USING A HETEROGENEOUS TRIFUNCTIONAL CATALYST | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-07-15 | — | — | WO | disclosed |
| US-20040127704-A1 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051306-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALOX15 4589/4885KMT2A 3685/4885HDAC3 2510/4885 |
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ALOX15 4399/4885KMT2A 3873/4885HDAC3 3007/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALOX15 4589/4885KMT2A 3685/4885HDAC3 2510/4885 |
| US-20240262847-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | ALOX15 4451/4885KMT2A 2080/4885HDAC3 1174/4885 |
| US-20040127704-A1 | Process for preparing diltiazem using a heterogeneous trifunctional catalyst | CYP2W1, INMT, TST | ALOX15 649/4885KMT2A 1171/4885HDAC3 2336/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | ALOX15 3782/4885KMT2A 3021/4885HDAC3 1181/4885 |
| US-20250269037-A1 | COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USE | PAICS, ORC3, SSB | ALOX15 3982/4885KMT2A 3038/4885HDAC3 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.